WO2012037928A3 - Verbindungen für die diagnostik neurodegenerativer erkrankungen am riechepithel - Google Patents

Verbindungen für die diagnostik neurodegenerativer erkrankungen am riechepithel Download PDF

Info

Publication number
WO2012037928A3
WO2012037928A3 PCT/DE2011/001780 DE2011001780W WO2012037928A3 WO 2012037928 A3 WO2012037928 A3 WO 2012037928A3 DE 2011001780 W DE2011001780 W DE 2011001780W WO 2012037928 A3 WO2012037928 A3 WO 2012037928A3
Authority
WO
WIPO (PCT)
Prior art keywords
compounds
neurodegenerative disorders
diagnosis
olfactory epithelium
disease
Prior art date
Application number
PCT/DE2011/001780
Other languages
English (en)
French (fr)
Other versions
WO2012037928A2 (de
Inventor
Boris Schmidt
Daniel Kieser
Alexander BOLÄNDER
Jochen Herms
Roland Hans Heyny-Von Haussen
Jiamin GU
Original Assignee
Klinikum Darmstadt Gmbh
Ludwig-Maximilians-Universität München
Technische Universität Darmstadt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Klinikum Darmstadt Gmbh, Ludwig-Maximilians-Universität München, Technische Universität Darmstadt filed Critical Klinikum Darmstadt Gmbh
Priority to US13/825,186 priority Critical patent/US20130287700A1/en
Priority to EP11804933.7A priority patent/EP2619591A2/de
Publication of WO2012037928A2 publication Critical patent/WO2012037928A2/de
Publication of WO2012037928A3 publication Critical patent/WO2012037928A3/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0039—Coumarin dyes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
    • G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
    • G01N21/64—Fluorescence; Phosphorescence
    • G01N21/6428—Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes"
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Optics & Photonics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)

Abstract

Gegenstand der vorliegenden Erfindung sind Verbindungen mit hoher Affinität für das Aß-Protein, α-Synuclein oder für Tau-PHF-Aggregate, welche als vorzugsweise fluoreszente Sonden für die in vivo Diagnostik von neurodegenerativen Erkrankungen geeignet sind, wie z.B. Alzheimer Demenz und Morbus Parkinson. Die Verbindungen zeichnen sich durch geeignete physikochemische Eigenschaften (Anregungswellenlänge, Emissionswellenlänge, Stokes-Shift, Extinktion) sowie hoher Affinität und Selektivität zu den Zielproteinen aus.
PCT/DE2011/001780 2010-09-20 2011-09-20 Verbindungen für die diagnostik neurodegenerativer erkrankungen am riechepithel WO2012037928A2 (de)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US13/825,186 US20130287700A1 (en) 2010-09-20 2011-09-20 Compounds for the diagnosis of neurodegenerative disorders on the olfactory epithelium
EP11804933.7A EP2619591A2 (de) 2010-09-20 2011-09-20 Verbindungen für die diagnostik neurodegenerativer erkrankungen am riechepithel

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102010045797A DE102010045797A1 (de) 2010-09-20 2010-09-20 Verbindungen für die Diagnostik neurodegenerativer Erkrankungen am Riechepithel
DE102010045797.3 2010-09-20

Publications (2)

Publication Number Publication Date
WO2012037928A2 WO2012037928A2 (de) 2012-03-29
WO2012037928A3 true WO2012037928A3 (de) 2013-04-25

Family

ID=45445673

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DE2011/001780 WO2012037928A2 (de) 2010-09-20 2011-09-20 Verbindungen für die diagnostik neurodegenerativer erkrankungen am riechepithel

Country Status (4)

Country Link
US (1) US20130287700A1 (de)
EP (1) EP2619591A2 (de)
DE (1) DE102010045797A1 (de)
WO (1) WO2012037928A2 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20150036349A (ko) * 2012-07-04 2015-04-07 바스프 에스이 하이드로존 잔기를 포함하는 유기 염료 및 염료-감응형 태양 전지에서의 이의 용도
WO2014165216A1 (en) * 2013-03-12 2014-10-09 The Trustees Of The University Of Pennsylvania Diagnosing and treating cancer
WO2015110263A1 (en) 2014-01-21 2015-07-30 Ac Immune Sa Carbazole and carboline compounds for use in the diagnosis, treatment, alleviation or prevention of disorders associated with amyloid or amyolid-like proteins
CN104531139B (zh) * 2015-01-06 2016-06-22 山西大学 一种咔唑类的pH荧光探针及其制备方法和应用
US9862682B2 (en) 2016-01-08 2018-01-09 BroadPharm Functionalized pegylated cyanine compounds, pharmaceutical compositions, and methods of use thereof
KR102646115B1 (ko) 2016-03-11 2024-03-12 에이씨 이뮨 에스에이 진단 및 치료를 위한 바이사이클릭 화합물
CA3073814C (en) * 2017-08-31 2023-02-14 Sanko Co., Ltd. N,n'-diarylurea derivative, manufacturing method thereof, and thermosensitive recording material using same
WO2019126565A1 (en) * 2017-12-20 2019-06-27 The Regents Of The University Of Colorado, A Body Corporate Lipid derivatives for in vitro or in vivo delivery
EP3802548A1 (de) 2018-06-08 2021-04-14 AC Immune SA Neuartige verbindungen zur diagnose
CN110054587B (zh) * 2019-05-31 2020-11-03 浙江工业大学 一种具有AIE特征的pH荧光化合物及其制备与应用
JP2023525081A (ja) 2020-05-07 2023-06-14 エーシー・イミューン・エス・アー 診断のための新規化合物
AU2022385416A1 (en) 2021-11-10 2024-05-02 Ac Immune Sa 4h-imidazo[1,5-b]pyrazole derivatives for diagnosis
WO2023083961A1 (en) 2021-11-10 2023-05-19 Ac Immune Sa Dihydropyrrolo[3,4-c]pyrazole derivatives and their use in diagnosis
WO2023083998A1 (en) 2021-11-10 2023-05-19 Ac Immune Sa Dihydropyrrolo[3,4c]-pyrazole derivatives and their use in diagnosis

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040152068A1 (en) * 2000-08-21 2004-08-05 Goldstein Lee E. Ocular diagnosis of Alzheimer's disease
WO2010074971A1 (en) * 2008-12-16 2010-07-01 Codman & Shurtleff, Inc. Use of nitrogen-containing curcumin analogs for the treatment alzheimer's disease
US20100190803A1 (en) * 2009-01-23 2010-07-29 Korea Institute Of Science And Technology Bis(styryl)pyrimidine or bis(styryl)benzene compounds, pharmaceutically acceptable salts thereof, preparation method thereof, and pharmaceutical composition for prevention or treatment of diseases featuring amyloids comprising the same as an active ingredient

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4260757A (en) * 1979-07-18 1981-04-07 Wiley Richard H Poly[di-1,2-(diazinylidene)-ethene-1,2-diols]
JPS57134417A (en) * 1981-02-14 1982-08-19 Meiji Seika Kaisha Ltd Cardiotonic agent
ES2536449T3 (es) 2000-08-24 2015-05-25 University Of Pittsburgh Of The Commonwealth System Of Higher Education Derivados de tioflavina para uso en diagnosis de la enfermedad de Alzheimer
US7597878B2 (en) 2000-09-19 2009-10-06 Li-Cor, Inc. Optical fluorescent imaging
EP2385032A1 (de) * 2002-11-08 2011-11-09 Takeda Pharmaceutical Company Limited GPR40 Rezeptorfunktionsregler
US8530483B2 (en) 2008-05-30 2013-09-10 Merck Sharp & Dohme Corp. Substituted azabenzoxazoles

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040152068A1 (en) * 2000-08-21 2004-08-05 Goldstein Lee E. Ocular diagnosis of Alzheimer's disease
WO2010074971A1 (en) * 2008-12-16 2010-07-01 Codman & Shurtleff, Inc. Use of nitrogen-containing curcumin analogs for the treatment alzheimer's disease
US20100190803A1 (en) * 2009-01-23 2010-07-29 Korea Institute Of Science And Technology Bis(styryl)pyrimidine or bis(styryl)benzene compounds, pharmaceutically acceptable salts thereof, preparation method thereof, and pharmaceutical composition for prevention or treatment of diseases featuring amyloids comprising the same as an active ingredient

Non-Patent Citations (15)

* Cited by examiner, † Cited by third party
Title
ALEXANDER BOLÄNDER ET AL: "Bis(arylvinyl)pyrazines, -pyrimidines, and -pyridazines As Imaging Agents for Tau Fibrils and [beta]-Amyloid Plaques in Alzheimer's Disease Models", JOURNAL OF MEDICINAL CHEMISTRY, vol. 55, no. 21, 8 November 2012 (2012-11-08), pages 9170 - 9180, XP055053909, ISSN: 0022-2623, DOI: 10.1021/jm300653b *
BULIC B ET AL: "Tau protein and tau aggregation inhibitors", NEUROPHARMACOLOGY, PERGAMON PRESS, OXFORD, GB, vol. 59, no. 4-5, 1 September 2010 (2010-09-01), pages 276 - 289, XP027234240, ISSN: 0028-3908, [retrieved on 20100210] *
CHARLES DUYCKAERTS ET AL: "Classification and basic pathology of Alzheimer disease", ACTA NEUROPATHOLOGICA, SPRINGER, BERLIN, DE, vol. 118, no. 1, 21 April 2009 (2009-04-21), pages 5 - 36, XP019713411, ISSN: 1432-0533 *
EVGUENI E. NESTEROV ET AL: "In Vivo Optical Imaging of Amyloid Aggregates in Brain: Design of Fluorescent Markers", ANGEWANDTE CHEMIE INTERNATIONAL EDITION, vol. 44, no. 34, 26 August 2005 (2005-08-26), pages 5452 - 5456, XP055035157, ISSN: 1433-7851, DOI: 10.1002/anie.200500845 *
H. XIONG ET AL: "ABCG2 Is Upregulated in Alzheimer's Brain with Cerebral Amyloid Angiopathy and May Act as a Gatekeeper at the Blood-Brain Barrier for A 1-40 Peptides", JOURNAL OF NEUROSCIENCE, vol. 29, no. 17, 29 April 2009 (2009-04-29), pages 5463 - 5475, XP055054286, ISSN: 0270-6474, DOI: 10.1523/JNEUROSCI.5103-08.2009 *
JEYANTHY SUTHARSAN ET AL: "Rational Design of Amyloid Binding Agents Based on the Molecular Rotor Motif", CHEMMEDCHEM, vol. 5, no. 1, 4 January 2010 (2010-01-04), pages 56 - 60, XP055034870, ISSN: 1860-7179, DOI: 10.1002/cmdc.200900440 *
KARUPPAGOUNDER S S ET AL: "Thiamine deficiency induces oxidative stress and exacerbates the plaque pathology in Alzheimer's mouse model", NEUROBIOLOGY OF AGING, TARRYTOWN, NY, US, vol. 30, no. 10, 1 October 2009 (2009-10-01), pages 1587 - 1600, XP026521811, ISSN: 0197-4580, [retrieved on 20080410], DOI: 10.1016/J.NEUROBIOLAGING.2007.12.013 *
LI FENG ET AL: "Fluorescence imaging of APP in Alzheimer's disease with quantum dot or Cy3: a comparative study", JOURNAL OF CENTRAL SOUTH UNIVERSITY, vol. 35, no. 9, 1 September 2010 (2010-09-01), pages 903 - 909, XP055054288, Retrieved from the Internet <URL:http://xbyx.xysm.net/xbwk/fileup/PDF/201009903.pdf> [retrieved on 20130222], DOI: 10.3969/j.issn.1672-7347.2010.09.001 *
M. W. LIU ET AL: "A New Series of Blue Emitting Pyrazine Derivatives for Organic Electroluminescence Devices", PHYSICA STATUS SOLIDI, vol. 185, no. 2, 14 May 2001 (2001-05-14), pages 203 - 211, XP055054282, Retrieved from the Internet <URL:http://onlinelibrary.wiley.com/doi/10.1002/1521-396X%28200106%29185:2%3C203::AID-PSSA203%3E3.0.CO;2-C/pdf> [retrieved on 20130222], DOI: 10.1002/1521-396X(200106)185:2<203::AID-PSSA203>3.0.CO;2-C *
QIAN LI ET AL: "Styryl-Based Compounds as Potential in vivo Imaging Agents for â-Amyloid Plaques", CHEMBIOCHEM - A EUROPEAN JOURNAL OF CHEMICAL BIOLOGY, WILEY VCH, WEINHEIM, DE, vol. 8, no. 14, 24 September 2007 (2007-09-24), pages 1679 - 1687, XP002643260, ISSN: 1439-4227, [retrieved on 20070820], DOI: 10.1002/CBIC.200700154 *
STEVEN E. ARNOLD ET AL: "Olfactory epithelium amyloid-[beta] and paired helical filament-tau pathology in Alzheimer disease", ANNALS OF NEUROLOGY, vol. 67, no. 4, 1 April 2010 (2010-04-01), pages 462 - 469, XP055034996, ISSN: 0364-5134, DOI: 10.1002/ana.21910 *
SYLVAIN ACHELLE ET AL: "V-Shaped 4,6-Bis(arylvinyl)pyrimidine Oligomers: Synthesis and Optical Properties", THE JOURNAL OF ORGANIC CHEMISTRY, vol. 74, no. 10, 15 May 2009 (2009-05-15), pages 3711 - 3717, XP055034983, ISSN: 0022-3263, DOI: 10.1021/jo900107u *
WU F Y ET AL: "2,5-di-[2-(3,5-bis(2-pyridylmethyl)amine -4-hydroxy-phenyl) ethylene] pyrazine zinc complex as fluorescent probe for labeling proteins", SPECTROCHIMICA ACTA. PART A: MOLECULAR AND BIOMOLECULAR SPECTROSCOPY, ELSEVIER, AMSTERDAM, NL, vol. 70, no. 5, 1 October 2008 (2008-10-01), pages 1127 - 1133, XP023785726, ISSN: 1386-1425, [retrieved on 20071101], DOI: 10.1016/J.SAA.2007.10.028 *
ZEMIN LI ET AL: "The Effect of Molecular Structure on the Photophysical Behavior of Substituted Styryl Pyrazine Derivatives", JOURNAL OF FLUORESCENCE, vol. 7, no. 3, 1 September 1997 (1997-09-01), pages 237 - 242, XP055054284, Retrieved from the Internet <URL:http://download.springer.com/static/pdf/378/art%253A10.1007%252FBF02758224.pdf?auth66=1362847685_0fcc1a82d6de8935768a1cfc04244313&ext=.pdf> [retrieved on 20130222], DOI: http://rd.springer.com/article/10.1007%2FBF02758224?LI=true *
ZIJUN LIU ET AL: "Two-photon absorption enhancement induced by aggregation due to intermolecular hydrogen bonding in V-shaped 2-hydroxypyrimidine derivatives", CHEMICAL COMMUNICATIONS, no. 19, 1 January 2008 (2008-01-01), pages 2260, XP055034979, ISSN: 1359-7345, DOI: 10.1039/b718147g *

Also Published As

Publication number Publication date
WO2012037928A2 (de) 2012-03-29
DE102010045797A1 (de) 2012-03-22
EP2619591A2 (de) 2013-07-31
US20130287700A1 (en) 2013-10-31

Similar Documents

Publication Publication Date Title
WO2012037928A3 (de) Verbindungen für die diagnostik neurodegenerativer erkrankungen am riechepithel
AR077016A1 (es) Uso de un anticuerpo anti-tau ps422 para el tratamiento de enfermedades cerebrales
WO2017053807A3 (en) Optimized variants of anti-vegf antibodies
WO2007024846A3 (en) Anit-il-23 antibiodies
WO2019098763A3 (ko) 알파-시누클레인에 대한 항체 및 그 용도
WO2010011999A3 (en) Methods and compositions for eliciting an amyloid-selective immune response
WO2008034016A3 (en) Assays for detecting native-state proteins and identifying compounds that modulate the stability of native-state proteins
CO6640211A2 (es) Composiciones del péptido a-beta y métodos
MA38248A1 (fr) Compositions pesticides et procédés associés
WO2009135857A3 (de) Polyurethane als rheologiemodifizierende mittel für kosmetische zubereitungen
EP2940017A3 (de) Verfahren zur Herstellung von als Hemmer der ATR-Kinase nützlichen Verbindungen
WO2012041292A3 (de) Verbindungen für die diagnostik neurodegenerativer erkrankungen an der retina
WO2010059242A3 (en) Neurodegenerative disease diagnostic compositions and methods of use
WO2008091948A3 (en) Galectin-3-binding, protein as a biomarker of cardiovascular disease
WO2011133441A3 (en) Novel synthesis for thiazolidinedione compounds
CL2007003875A1 (es) Compuestos derivados de amidas del acido 3-amino tetrahidrofurano-3-carboxilico; procedimiento de preparacion de dichos compuestos.
WO2011003100A3 (en) Compositions and methods for diagnosing and/or treating influenza infection
WO2013028334A3 (en) Use of small molecules in methods for purification of biomolecules
WO2006075139A3 (en) Novel process for the preparation of substituted indoles
WO2010010435A3 (en) Fused oxazole and thiazole derivatives as trpms modulators
WO2009053446A3 (en) Pregabalin intermediates and process for preparing them and pregabalin
WO2013116668A3 (en) Diagnostic peptides for lyme disease
WO2015117088A3 (en) Antibody based reagents that specifically recognize neurodegenerative disease related forms of the protein tdp-43
WO2013063412A3 (en) Methods of diagnosis and treatment of endoplasmic reticulum (er) stress-related conditions
WO2014053110A3 (de) Peptide zur behandlung und frühdiagnose von morbus alzheimer und anderer tauopathien

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11804933

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2011804933

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 1120111041543

Country of ref document: DE

WWE Wipo information: entry into national phase

Ref document number: 13825186

Country of ref document: US